We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current FARN market cap is 80.82M. The company's latest EPS is EUR -0.4177 and P/E is -2.81.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 19k | 0 | 0 | 0 | 0 |
| Operating Income | -19.99M | -13.1M | -16.65M | -21.11M | -27.43M |
| Net Income | -20.09M | -13.26M | -16.95M | -21.19M | -28.73M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 8M | 10.21M | 8.37M | 13.18M | 11.27M |
| Total Liabilities | 7.63M | 8.6M | 10.22M | 10.26M | 22.75M |
| Total Equity | 369k | 1.61M | -1.85M | 2.92M | -11.48M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -20.53M | -11.52M | -17.48M | -22.22M | -22.99M |
| Investing | -295k | -100k | -142k | -473k | -385k |
| Financing | 15.54M | 14.61M | 14.79M | 25.59M | 23.48M |
| Market Cap | 80.82M |
| Price to Earnings Ratio | -2.81 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 11.56 |
| Price to Book Ratio | -7.04 |
| Dividend Yield | - |
| Shares Outstanding | 68.79M |
| Average Volume (1 week) | 25.17k |
| Average Volume (1 Month) | 27.27k |
| 52 Week Change | -63.17% |
| 52 Week High | 360.00 |
| 52 Week Low | 117.50 |
| Spread (Intraday) | 5 (4.17%) |
| Company Name | Faron Pharmaceuticals Oy |
| Address |
joukahaisenkatu 6, intelligate turku FIN-20520 |
| Website | https://www.faronpharmaceuticals.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
